-
A Phase 3 Open-Label Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Push Compared with Intravenous Amivantamab or Subcutaneous Amivantamab Administered via On Body Delivery System in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy.
You can participate in this study if you are diagnosed with advanced lung cancer. The purpose of this study is to know the efficacy and ...Phase
Interventional
